Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry

Detection and monitoring of minimal residual disease by quantitative real-time PCR.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Evaluation of BM cytomorphology after allo-SCT in patients with AML

NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Acute Myeloid Leukemia

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Clinical Analysis and Optimization of Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Residual Disease as Determined by Flow Cytometry.

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry

Detection and monitoring of minimal residual disease by quantitative real-time PCR.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Evaluation of BM cytomorphology after allo-SCT in patients with AML

NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Acute Myeloid Leukemia

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Clinical Analysis and Optimization of Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Residual Disease as Determined by Flow Cytometry.

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry

Detection and monitoring of minimal residual disease by quantitative real-time PCR.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.